[HTML][HTML] Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer

A Argiris, MV Karamouzis, WE Gooding… - Journal of Clinical …, 2011 - ncbi.nlm.nih.gov
A Argiris, MV Karamouzis, WE Gooding, BF Branstetter, S Zhong, LE Raez, P Savvides…
Journal of Clinical Oncology, 2011ncbi.nlm.nih.gov
Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head
and Neck Cancer - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI
Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text Archive
Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC3083869 Other
Formats PubReader PDF (136K) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J …
Abstract
Purpose
We hypothesized that bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN).
ncbi.nlm.nih.gov